Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 16, Number 8—August 2010

Possible Recurrent Pandemic (H1N1) 2009 Infection, Israel

Cite This Article

To the Editor: We report 2 cases of possible recurrent laboratory-confirmed infection with pandemic (H1N1) 2009 virus in Israel. Patient 1, a 24-year-old man, had Noonan syndrome (1,2). He was hospitalized on August 10, 2009, because of high-grade fever and cough. At admission, a nasopharyngeal specimen was collected for pandemic (H1N1) 2009 virus real-time reverse transcription–PCR (RT-PCR) (ABI 7500; Applied Biosystems, Foster City, CA, USA) for the pandemic hemagglutinin gene; a validated in-house protocol developed at Israel Central Virology Laboratory was used, as previously described (3). Briefly, the in-house assay was validated against the assay for pandemic (H1N1) 2009 virus developed by the Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA). The in-house assay was as sensitive as the CDC assay; however, the in-house primers and probes were more specific for detecting pandemic (H1N1) 2009 virus with 105% amplification efficiency of viral RNA that was logarithmically serially diluted. In addition, of 100 samples tested side by side with the in-house and CDC assays, 75 samples were positive by both assays, and 25 were negative by both assays; thus, the sensitivity and specificity of the in-house assay were 100%.

The patient was not treated with neuraminidase inhibitors and did not require supportive treatment; after 1 day of hospitalization, he was discharged with a diagnosis of upper respiratory tract infection. The laboratory subsequently reported the RT-PCR as positive for pandemic (H1N1) 2009 virus. On November 22, the man was hospitalized again for dyspnea and fever. The RT-PCR result from a nasopharyngeal sample collected at admission was positive. Hemagglutination-inhibition assay demonstrated a high titer (320) of serum antibody against pandemic (H1N1) 2009 virus in a blood sample taken at admission. The patient took oseltamivir for 5 days, and his condition markedly improved. Result of a repeat RT-PCR at discharge was negative.

An identical neuraminidase gene sequence was detected during both illness episodes (August and November). The specimens were also tested with an experimental RT-PCR assay for rapid detection of the oseltamivir resistance mutation H275Y on the pandemic neuraminidase gene (4). For specimens collected during both episodes, the virus was oseltamivir sensitive.

Patient 2, a 13.5-year-old boy, had severe cerebral palsy. On July 27, 2009, high-grade fever with dyspnea developed. He was treated as an outpatient for 5 days with oseltamivir and clinically improved. However, on August 11, he had fever with respiratory distress and was hospitalized. RT-PCR for pandemic (H1N1) 2009 virus was positive on August 14. A second course of oseltamivir was administered for 10 days with the dosage adjusted for age and doubled from that of the previous regimen. Further testing with the experimental rapid RT-PCR indicated the viral strain had the oseltamivir resistance mutation. On September 14, RT-PCR was negative.

On December 11, the boy was again hospitalized because of respiratory distress and high-grade fever. On December 14, RT-PCR was positive for pandemic (H1N1) 2009 virus, and a 5-day regimen of oseltamivir was started. Another specimen taken the same day was negative. A high serum antibody titer (320) to pandemic (H1N1) 2009 virus was measured by hemagglutination-inhibition assay on December 16; no oseltamivir resistance mutation was found. Additional laboratory testing included a complete panel for respiratory viruses, which was negative for human metapneumovirus; respiratory syncytial virus; adenovirus; seasonal influenza virus types A and B; and parainfluenza virus types 1, 2, and 3.

These 2 cases of possible recurrent pandemic (H1N1) 2009 infection demonstrated a wide interval between illness episodes. Neither patient had accompanying immunodeficiency, and both had antibody titers far beyond the accepted seroprotective threshold for influenza (5), albeit ineffective. These titers probably resulted from primary infection rather than from subclinical exposure, which manifests itself as a lower titer by order of magnitude (6,7).

Virus clearance was not laboratory confirmed for patient 1 after the first episode because no samples were taken after hospital discharge. Patient 2 had both positive and negative RT-PCRs for pandemic (H1N1) 2009 virus (Table) from samples collected the same day during the second hospitalization, which also may disprove reinfection. The positive result could be explained by laboratory contamination during the RT-PCR processing that indicated a false-positive result. However, contamination is unlikely because each run of the RT-PCR was routinely accompanied by runs of negative controls (that contain water) to rule out such contamination. Nonanalytic factors such as specimen misidentification also are unlikely because the central virology laboratory, which is the national reference center, has an ISO-9000 qualification from the Standards Institution of Israel ( Furthermore, no other respiratory virus was found by laboratory testing at that time. The patient was infected with an oseltamivir-resistant pandemic (H1N1) 2009 virus during the first illness episode and with an oseltamivir-sensitive virus during the second episode and had 2 RT-PCRs with negative results between the episodes.

The novel pandemic influenza virus may be able to reinfect certain chronically ill persons. Caregivers should be aware of this trait when considering the differential diagnosis of influenza-like illness in a patient with a documented, and even treated, pandemic (H1N1) 2009 infection.



We thank the medical team and administrative staff of the epidemiology unit, the respiratory intensive care unit, and the pediatric intensive care unit of Sheba Medical Center, Tel Hashomer, for their cooperation. We also thank Shalom Bronstein for proofreading.


Eran Kopel1Comments to Author , Michal Mandelboim1, Ziva Amitai, Itamar Grotto, Musa Hindiyeh, Ehud Kaliner, Ella Mendelson, and Irina Volovik
Author affiliations: Ministry of Health, Tel Aviv, Israel (E. Kopel, Z. Amitai, E. Kaliner, I. Volovik); Ministry of Health, Ramat Gan, Israel (M. Mandelboim, M. Hindiyeh, E. Mendelson); Ministry of Health, Jerusalem, Israel (I. Grotto)



  1. Noonan  JA. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child. 1968;116:37380.PubMedGoogle Scholar
  2. Allanson  JE. Noonan syndrome [review]. J Med Genet. 1987;24:913. DOIPubMedGoogle Scholar
  3. Panning  M, Eickmann  M, Landt  O, Monazahian  M, Ölschläger  S, Baumgarte  S, Detection of influenza A(H1N1)v virus by real-time RT-PCR. Euro Surveill. 2009;14:pii: 19329.
  4. Hindiyeh  M, Ram  D, Mandelboim  M, Meningher  T, Hirsh  S, Robinov  J, Rapid detection of influenza A pandemic (H1N1) 2009 virus neuraminidase resistance mutation H275Y by real-time RT-PCR. J Clin Microbiol. 2010;48:18847. DOIPubMedGoogle Scholar
  5. Potter  CW, Oxford  JS. Determinants of immunity to influenza infection in man. Br Med Bull. 1979;35:6975.PubMedGoogle Scholar
  6. Greenberg  ME, Lai  MH, Hartel  GF, Wichems  CH, Gittleson  C, Bennet  J, Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009;361:240513. DOIPubMedGoogle Scholar
  7. Nolan  T, McVernon  J, Skeljo  M, Richmond  P, Wadia  U, Lambert  S, Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA. 2009;303:3746. DOIPubMedGoogle Scholar




Cite This Article

DOI: 10.3201/eid1608.100436

1These authors contributed equally to this article.

Related Links


Table of Contents – Volume 16, Number 8—August 2010

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Eran Kopel, Tel Aviv District Health Office, Ministry of Health, 12 Ha'arba'ah St, POB 20301, Tel Aviv 61203, Israel

Send To

10000 character(s) remaining.


Page created: March 30, 2011
Page updated: March 30, 2011
Page reviewed: March 30, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.